-
-
-
-
-
-
-
Brookline Capital Markets Starts Marker Therapeutics (MRKR) at Buy
-
-
-
-
-
-
-
Marker Therapeutics (MRKR) Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

